Siqi Dai1,2, Shuang Xu3, Yao Ye1,2, Kefeng Ding1,2. 1. Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. 2. Zhejiang University Cancer Center, Hangzhou, China. 3. Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China.
Abstract
BACKGROUND: Despite recent advance in immune therapy, great heterogeneity exists in the outcomes of colorectal cancer (CRC) patients. In this study, we aimed to analyze the immune-related gene (IRG) expression profiles from three independent public databases and develop an effective signature to forecast patient's prognosis. METHODS: IRGs were collected from the ImmPort database. The CRC dataset from The Cancer Genome Atlas (TCGA) database was used to identify a prognostic gene signature, which was verified in another two CRC datasets from the Gene Expression Omnibus (GEO). Gene function enrichment analysis was conducted. A prognostic nomogram was built incorporating the IRG signature with clinical risk factors. RESULTS: The three datasets had 487, 579, and 224 patients, respectively. A prognostic six-gene-signature (CCL22, LIMK1, MAPKAPK3, FLOT1, GPRC5B, and IL20RB) was developed through feature selection that showed good differentiation between the low- and high-risk groups in the training set (p < 0.001), which was later confirmed in the two validation groups (log-rank p < 0.05). The signature outperformed tumor TNM staging for survival prediction. GO and KEGG functional annotation analysis suggested that the signature was significantly enriched in metabolic processes and regulation of immunity (p < 0.05). When combined with clinical risk factors, the model showed robust prediction capability. CONCLUSION: The immune-related six-gene signature is a reliable prognostic indicator for CRC patients and could provide insight for personalized cancer management.
BACKGROUND: Despite recent advance in immune therapy, great heterogeneity exists in the outcomes of colorectal cancer (CRC) patients. In this study, we aimed to analyze the immune-related gene (IRG) expression profiles from three independent public databases and develop an effective signature to forecast patient's prognosis. METHODS: IRGs were collected from the ImmPort database. The CRC dataset from The Cancer Genome Atlas (TCGA) database was used to identify a prognostic gene signature, which was verified in another two CRC datasets from the Gene Expression Omnibus (GEO). Gene function enrichment analysis was conducted. A prognostic nomogram was built incorporating the IRG signature with clinical risk factors. RESULTS: The three datasets had 487, 579, and 224 patients, respectively. A prognostic six-gene-signature (CCL22, LIMK1, MAPKAPK3, FLOT1, GPRC5B, and IL20RB) was developed through feature selection that showed good differentiation between the low- and high-risk groups in the training set (p < 0.001), which was later confirmed in the two validation groups (log-rank p < 0.05). The signature outperformed tumor TNM staging for survival prediction. GO and KEGG functional annotation analysis suggested that the signature was significantly enriched in metabolic processes and regulation of immunity (p < 0.05). When combined with clinical risk factors, the model showed robust prediction capability. CONCLUSION: The immune-related six-gene signature is a reliable prognostic indicator for CRC patients and could provide insight for personalized cancer management.
Authors: Manoj B Menon; Julia Gropengießer; Jessica Fischer; Lena Novikova; Anne Deuretzbacher; Juri Lafera; Hanna Schimmeck; Nicole Czymmeck; Natalia Ronkina; Alexey Kotlyarov; Martin Aepfelbacher; Matthias Gaestel; Klaus Ruckdeschel Journal: Nat Cell Biol Date: 2017-09-18 Impact factor: 28.824
Authors: René Adam; Valérie Delvart; Gérard Pascal; Adrian Valeanu; Denis Castaing; Daniel Azoulay; Sylvie Giacchetti; Bernard Paule; Francis Kunstlinger; Odile Ghémard; Francis Levi; Henri Bismuth Journal: Ann Surg Date: 2004-10 Impact factor: 12.969
Authors: Haoyu Ren; Alexandr V Bazhin; Elise Pretzsch; Sven Jacob; Haochen Yu; Jiang Zhu; Markus Albertsmeier; Lars H Lindner; Thomas Knösel; Jens Werner; Martin K Angele; Florian Bösch Journal: Mol Ther Oncolytics Date: 2021-12-09 Impact factor: 7.200